SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is trending following news of a significant institutional stake, with one investor now holding 91% of the shares. This has created an extremely tight float, igniting intense community discussion around an unprecedented short squeeze potential and a "float lock" that many believe will drive substantial price volatility as available shares become scarce.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending as investors discuss a recent dip, with some anticipating further entry points while others debate potential price levels. The conversation also points to broader drivers impacting recent small-cap movements.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market attention driven by recent compelling clinical trial data for its ANKTIVA treatment, demonstrating impressive complete response rates and durability in bladder cancer, coupled with a notable Saudi Arabian approval for lung cancer. The community is actively discussing a potential massive short squeeze, fueled by exceptionally high trading volume and a strong belief in the company's transformative potential in global cancer treatment. Investors are eyeing its long-term pipeline and the possibility of broader regulatory approvals expanding its market significantly.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd ($SUGP) is trending due to widespread community discussion focused on its ultra-low share float and significant short interest, sparking intense speculation about a potential short squeeze. Traders are actively drawing comparisons to past high-volatility stocks, with sentiment further fueled by a high cost to borrow and anticipation of upcoming earnings or contract news as potential catalysts for a substantial price movement.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following a significant upgrade by H.C. Wainwright & Co. to a Buy rating with an $80 price target, fueling broad bullish sentiment and discussions of a potential short squeeze. The community is actively speculating about imminent major AI cloud deals with new partners like Anthropic or xAI, further emphasizing IREN's strategic advantage with its existing power capacity and Microsoft contract in the booming AI infrastructure sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as community discussion heats up over recent college sports betting scandals and the evolving landscape of prediction markets, creating market volatility. This comes despite notable analyst upgrades and significant institutional buying, leading to a split in investor sentiment. Many are capitalizing on dips ahead of major sporting events and anticipated strong earnings, while frustrated investors lament perceived market manipulation and the stock's recent performance.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is surging due to robust early demand for its new oral Wegovy pill and the UK's approval of a higher injectable dose, reinforcing its competitive edge. With a key rival's oral GLP-1 pill facing an FDA delay, the community is enthusiastically discussing NVO's strengthened market position and potential for substantial growth in the obesity treatment sector.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to investor sentiment being impacted by delays surrounding the Digital Asset Market Clarity Act, affecting crypto-adjacent stocks. While some in the community view this as an overreaction and a buying opportunity, others are questioning Robinhood's ability to diversify its business model with initiatives like banking and prediction markets amidst regulatory headwinds.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is actively trending after its CEO highlighted robust demand for its AI/HPC data centers and confirmed ongoing discussions for new hyperscaler deals at a recent conference. The community views CIFR as a significant long-term play, often citing its power-first colocation model and existing contracts with major tech firms as reasons for substantial future upside. Despite widespread sentiment about market manipulation suppressing its price, investors remain confident in its strategic pivot beyond traditional Bitcoin mining within the expanding AI infrastructure sector.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is trending following a significant 10-year data center leasing agreement with AMD, signaling a strategic pivot towards AI and high-performance computing infrastructure. The community is actively discussing this development as a key step in re-rating the company as an infrastructure powerhouse with substantial power capacity, diversifying beyond its traditional Bitcoin mining operations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Deutsche Bank Aktiengesellschaft Boosts GSK (LON:GSK) Price Target to GBX 1,675

Deutsche Bank Aktiengesellschaft raised their price objective on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a "hold" rating in a research note on Thursday...

GSK (LON:GSK) Shares Pass Above 200-Day Moving Average - Here's Why

GSK (LON:GSK) Share Price Passes Above 200-Day Moving Average - Should You Sell...

GSK (NYSE:GSK) Stock Crosses Above 200-Day Moving Average - Here's Why

GSK (NYSE:GSK) Stock Crosses Above 200-Day Moving Average - Time to Sell...

Here's Why GSK (GSK) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?

MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.

Why GSK (GSK) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSKs B7-H3 Antibody Drug Conjugate (ADC)

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (GSK, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1...

Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth

Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.read more...

AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties

AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a dispute over Jemperli royalties and licensing rights.read more...

<ul class="summary-bullets"><li>JNJ agreed to drug discounts and tariff exemptions under a White House deal.</li><li>The agreement builds on its existing $55 billion U.S. manufacturing and R&amp;D plan.</li><li>New facilities add to projects already underway in North Carolina and Pennsylvania.</li></ul><p>Johnson &amp; Johnson (JNJ) said on Thursday it has reached a voluntary agreement with the U.S. government to expand access to medicines, lower drug costs for American patients, and secure exemptions from U.S. tariffs on its pharmaceutical products, while advancing its domestic manufacturing plans.</p><h2 class="st-heading-2"><strong>Drug Pricing And Tariff Exemptions</strong></h2><p>As part of the deal, JNJ will allow Americans to buy medicines at significantly discounted rates through TrumpRx.gov, a government-backed direct-to-patient platform. The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.</p><p>The deal grants JNJ’s pharmaceutical products exemptions from U.S. tariffs and aligns with the administration’s “most-favored-nation” pricing framework.</p><p>“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” CEO Joaquin Duato said in a statement.&nbsp;</p><h2 class="st-heading-2"><strong>US Manufacturing Commitments</strong></h2><p>JNJ said the agreement builds on its previously announced $55 billion U.S. investment plan through early 2029, which focuses on expanding domestic manufacturing, research and development, and technology.&nbsp;</p><p>As part of the plan, the company announced two additional U.S. manufacturing facilities, including a cell therapy site in Pennsylvania and a drug product manufacturing facility in North Carolina. Construction is already underway at the company’s $2 billion biologics facility in Wilson, North Carolina, a project expected to support around 5,000 manufacturing and construction jobs.&nbsp;</p><p>Separately, JNJ has committed $2 billion over the next 10 years to a biopharmaceutical site in Holly Springs, North Carolina, which is expected to create about 120 jobs. The company said it expects to announce further U.S. investments later this year.</p><h2 class="st-heading-2"><strong>White House Drug Deals Expand</strong></h2><p>The announcement follows&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-strikes-new-drug-price-deals-with-roche-novartis-merck-and-other-pharma-giants/cLe0duBREtP">similar agreements struck last month</a> between the White House and other major drugmakers, including Amgen, Bristol Myers Squibb, Pfizer, Gilead Sciences, GSK, Merck, Novartis, Roche and Sanofi.</p><p>The deals require steep discounts through TrumpRx, most-favored-nation pricing for Medicaid, expanded U.S. manufacturing, and restrictions on stockpiling drugs to avoid tariffs.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment was ‘bearish’ amid ‘high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/jnj_ss_png_1d85f7828a.webp" alt="jnj ss.png" width="967" height="142"><figcaption>JNJ sentiment and message volume as of January 8| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/JNJ">JNJ’s stock</a> has risen 49% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs 

The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.

Equity

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GSK News

GSKGlaxosmithkline plc - ADR